Conzo G, Docimo G, Ruggiero R, Napolitano S, Palazzo A, Gambardella C, Mauriello C, Tartaglia E, Cavallo F, Santini L
Department of Anaesthesiologic, VII Division of General and Endocrine Surgery, Surgical and Emergency Sciences, Second University of Naples, Italy.
G Chir. 2012 Oct;33(10):339-42.
BACKGROUND: In the treatment of differentiated thyroid cancer (DTC), in absence of enlarged lymph nodes, the role of routine central lymph node dissection (RCLD) remains controversial. The aim of this study is to analyze data resulting from total thyroidectomy (TT) not combined with RCLD in the treatment of DTC. METHODS: We retrospectively evaluated the clinical records of 80 patients treated between January 1996 and December 2003 with TT without RCLND, in absence of suspected enlarged lymph nodes at preoperative ultrasonography and intraoperatively during neck exploration. In this series, 75 patients (93.7%) underwent radioiodine (RAI) ablation, followed by Thyroid Stimulating Hormone (TSH) suppression therapy. In case of locoregional lymph nodal recurrence, a central (VI) and ipsilateral (III-IV) selective lymph node dissection was performed. RESULTS: Incidence of permanent hypoparathyroidism (iPTH < 10 pg/ml) and unilateral temporary vocal fold paralysis were respectively 2.55% and 2.55%. Locoregional recurrence, with positive cervical lymph nodes, after a 10.3 ± 4.7 years mean follow-up was observed in 3 patients (3.75%). They were submitted to a central (VI) and ipsilateral (III-IV) selective neck dissection without significant complications. CONCLUSIONS: In our series, TT not combined with RCLD was associated to a low locoregional recurrence rate, even if the lack of a control group treated with RCLD does not allow any generalized assumption. RCLD may be indicated in high risk patients, in whom lymph nodal recurrence is more frequent. More prospective randomized studies are needed to better define the role of RCLD and postoperative radioiodine ablation.
背景:在分化型甲状腺癌(DTC)的治疗中,在无肿大淋巴结的情况下,常规中央区淋巴结清扫术(RCLD)的作用仍存在争议。本研究的目的是分析全甲状腺切除术(TT)不联合RCLD治疗DTC所产生的数据。 方法:我们回顾性评估了1996年1月至2003年12月期间接受TT且未行RCLND治疗的80例患者的临床记录,这些患者术前超声检查及术中颈部探查均未发现可疑肿大淋巴结。在该系列中,75例患者(93.7%)接受了放射性碘(RAI)消融,随后进行促甲状腺激素(TSH)抑制治疗。若出现局部区域淋巴结复发,则进行中央区(VI区)和同侧(III-IV区)选择性淋巴结清扫术。 结果:永久性甲状旁腺功能减退(iPTH < 10 pg/ml)和单侧暂时性声带麻痹的发生率分别为2.55%和2.55%。平均随访10.3±4.7年后,3例患者(3.75%)出现局部区域复发且颈部淋巴结阳性。他们接受了中央区(VI区)和同侧(III-IV区)选择性颈部清扫术,未出现明显并发症。 结论:在我们的系列研究中,TT不联合RCLD与较低的局部区域复发率相关,尽管缺乏接受RCLD治疗的对照组,无法进行任何普遍的推断。RCLD可能适用于淋巴结复发更频繁的高危患者。需要更多前瞻性随机研究来更好地确定RCLD和术后放射性碘消融的作用。
Taehan Yongsang Uihakhoe Chi. 2020-9
Front Endocrinol (Lausanne). 2022